BMO Capital analyst Evan Seigerman raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $545 from $520 and keeps an Outperform rating on the shares. The FDA approval of Suzetrigine, now Journavx, for the treatment of acute pain clears the path to a U.S. launch and crystallizes Vertex’s story for growth beyond cystic fibrosis, the analyst tells investors in a research note. This new non-opioid treatment option for acute pain patients is poised for strong uptake, the firm adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Early notable gainers among liquid option names on January 31st
- Vertex Pharmaceuticals price target raised to $433 from $430 at Scotiabank
- Vertex Pharmaceuticals price target raised to $550 from $535 at H.C. Wainwright
- Vertex Pharmaceuticals price target lowered to $320 from $325 at Baird
- Vertex Pharmaceuticals price target raised to $435 from $418 at Barclays